Recombinant Human Mesothelin (aa 296-580) His Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Mesothelin, also known as CAK1 and ERC, is derived from a 70 kDa precursor that also includes Megakaryocyte Potentiating Factor (MPF) (1-3). The 70 kDa precursor is expressed on the cell surface where it is cleaved at a dibasic proteolytic site to release the 32 kDa glycosylated MPF (3, 4). MPF is a cytokine that potentiates IL-3 induced megakaryocyte colony formation (2, 5). The term Mesothelin refers to the 40 kDa glycosylated protein which remains attached to the cell surface via a GPI linkage. Alternate splicing generates additional Mesothelin isoforms that have either an eight amino acid insertion following Ser408 or a substituted C‑terminal region with no GPI anchor (6). This recombinant human Mesothelin lacks the 8 aa insertion, and within aa 296-580 it shares 59% sequence identity with mouse and rat Mesothelin. Mesothelin is normally expressed on mesothelial cells in the pleura, pericardium, and peritoneum as well as in the developing and postnatal pancreas (1, 7). It is up‑regulated in mesotheliomas and a range of carcinomas and adenomas (8 ‑ 11). Mesothelin promotes tumor cell proliferation, migration, anchorage-independent growth, and tumor progression (10, 12). It is coexpressed with the tumor antigen CA125/MUC16 on advanced ovarian adenocarcinomas and interacts with this molecule to support cell adhesion (13). A soluble form of Mesothelin is released from tumor cells into the serum or tissue effusions (11, 14, 15).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: Binding Assay, Bioassay, Flow Cytometry.

Showing Publications 1 - 4 of 4.

Publications using 3265-MS	Applications	Species
A Duran, PE Guerrero, MR Ortiz, D Pérez Del, E Castro, A Garcia-Vel, E Fort, R de Llorens, R Saldova, E Llop, R Peracaula Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients' Sera Biomedicines, 2022-08-10;10(8):. 2022-08-10 [PMID: 36009489] (Human)		Human
JK Fierle, J Abram-Sali, V Atsaves, M Brioschi, M de Tiani, P Reichenbac, M Irving, G Coukos, SM Dunn A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors Scientific Reports, 2022-01-21;12(1):1136. 2022-01-21 [PMID: 35064152] (Flow Cytometry, Human)	Flow Cytometry	Human
C Montemagno, S Bacot, M Ahmadi, B Kerfelec, D Baty, M Debiossat, A Soubies, P Perret, L Riou, D Fagret, A Broisat, C Ghezzi Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer J. Nucl. Med., 2018-03-23;0(0):. 2018-03-23 [PMID: 29572256] (Bioassay, Human)	Bioassay	Human
Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin N, Nguyen M, Jean-Mary G, Tong X, Uppal P, Korochkina S, Forbes B, Chen T, Righi E, Bronson R, Chen H, Orsulic S, Brauns T, LeBlanc P, Scholler N, Dranoff G, Gelfand J, Poznansky M A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol, 2014-02-24;7(0):15. 2014-02-24 [PMID: 24565018] (Binding Assay)	Binding Assay

Array 3265-MS

• Mesothelin Antibodies
• Mesothelin Lysate
• Mesothelin Protein
• Mesothelin Proteins and Enzymes
• Mesothelin ELISAs